Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio
Sandoz, a global leader in generic and biosimilar medicines, has successfully completed the acquisition of worldwide brand rights for leading systemic antifungal agent Mycamine ® (micafungin sodium, Funguard® in Japan) from Astellas. Through this acquisition of the leading global echinocandin, one of three…
Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the company’s Phase 3 clinical program, CORALreef, for MK-0616, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, being evaluated for…
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided an update on the Phase 3 LEAP-010 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor…
Deargen and Serengen Partner to Accelerate Drug Discovery
Serengen and Deargen are excited to announce their collaboration to accelerate the drug discovery process. This strategic partnership brings together Serengen’s novel DNA encoded library (DEL) technology with Deargen’s leading AI-driven drug discovery platform, known as DearDTI. The world of drug discovery is…
Navigating Challenges and Opportunities in the Esophagoscopes Market: A Comprehensive Analysis Across 39 Countries to 2033 – ResearchAndMarkets.com
The “Esophagoscopes Market Size by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures and Forecast to 2033” database has been added to ResearchAndMarkets.com’s offering. This report was built to visualize quantitative market trends within Endoscopy Devices therapeutic area. The model discusses…
RQM+™ acquires Germany-based CRO Kottmann
RQM+, the global leader in medtech services, announces the acquisition of CRO Kottmann, a leading contract research organization (CRO) renowned for its unparalleled customer service, clinical research and its commitment to quality in the key German market. This major transaction confirms…
Anthem Blue Cross and Blue Shield Introduces Anthem Link Virtual First Health Plans, Helping Members Access Convenient, Affordable Care Options
Anthem Blue Cross and Blue Shield in Connecticut today announced its Anthem Link Virtual First health plans to eligible members in select commercial health plans. Anthem Link Virtual First plans give individuals affordable access to virtual care options, including access…
U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Reblozyl® (luspatercept-aamt) for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who…
LIB Therapeutics Announces Positive Results from the Phase 3 Long-term Efficacy and Safety of Lerodalcibep in Heterozygous Familial Hypercholesterolemia (LIBerate-HeFH) Trial
LIB Therapeutics Inc., a clinical-stage biopharmaceutical company developing subcutaneous and oral PCSK9 inhibitor medicines for patients at very high and high risk of cardiovascular disease (“CVD”) requiring additional reductions in LDL- cholesterol (“LDL-C” or “LDL”), in patients on maximally tolerated…
Octave® Bioscience, Inc.’s Solution for Transforming the Care Paradigm in MS has been Selected as a Finalist in Fast Company’s 2023 Innovation by Design Awards
Octave® Bioscience, Inc. was honored in Fast Company’s Innovation by Design Awards for 2023 in the Health category. The Innovation by Design Awards, which can be found in the September 2023 issue of Fast Company, honor the designers and businesses solving the most crucial…
Global Vital Signs Monitoring Devices Market Outlook & Forecast Report 2023: A $33.35+ Billion Industry by 2028 – Patient-Centric Digital Systems and Wearable Devices Drive Growth – ResearchAndMarkets.com
The global vital signs monitoring devices market is expected to reach a value of $33.36 billion by 2028 from $20.6 billion in 2022, growing at a CAGR of 8.36% from 2022 to 2028 The North American region dominated the vital…
inSpring and MGH Institute of Health Professions Team Up to Meet Critical Demand for Nurses
inSpring, a leading health care and technology talent mobility company specializing in connecting diverse, highly-skilled international job candidates in the United States with employment opportunities in nursing and technology, announced today a groundbreaking partnership with Mass General Brigham’s esteemed graduate school, MGH Institute…